Enhancement of Anti-tumor Activity of Newcastle Disease Virus by the Synergistic Effect of Cytosine Deaminase |
Lv, Zheng
(College of Life Science of Northeast Agricultural University)
Zhang, Tian-Yuan (College of Life Science of Northeast Agricultural University) Yin, Jie-Chao (College of Life Science of Northeast Agricultural University) Wang, Hui (College of Life Science of Northeast Agricultural University) Sun, Tian (College of Life Science of Northeast Agricultural University) Chen, Li-Qun (National Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences) Bai, Fu-Liang (College of Life Science of Northeast Agricultural University) Wu, Wei (National Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences) Ren, Gui-Ping (College of Life Science of Northeast Agricultural University) Li, De-Shan (College of Life Science of Northeast Agricultural University) |
1 | Huber BE, Austin EA, Richards CA, et al (1994). Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA, 9, 18302-6. |
2 | Ichikawa T, Tamiya T, Adachi Y, et al (2000). In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. Cancer Gene Ther, 7, 74-82. DOI ScienceOn |
3 | Kaliberova LN, Manna DLD, Krendelchtchikova V, et al (2008). Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene. Mol Cancer Ther, 7, 2845-54. DOI ScienceOn |
4 | Karcher J, Dyckhoff G, Beckhove P, et al (2004). Anti-tumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res, 64, 8057-61. DOI ScienceOn |
5 | Khatri A, Zhang B, Doherty E, et al (2006). Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice. J Gene Med, 8, 1086-96. DOI ScienceOn |
6 | Knipe DM, Howley PM, Griffin DE, et al (2006). Fields virology. 5th ed, Philly, Lippincott Williams & Wilkins. |
7 | Liang W, Wang H, Sun TM, et al (2003). Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterol, 9, 495-98. DOI |
8 | Nakaya T, Cros J, Park MS, et al (2001). Recombinant Newcastle disease virus as a vaccine vector. J Virol, 75, 11868-73. DOI ScienceOn |
9 | Negroni L, Samson M, Guigonis J, et al (2007). Treatment of colon cancer cells using the cytosine deaminase/5-fluorocytosine suicide system induces apoptosis, modulation of the proteome and phosphorylation. Mol Cancer Ther, 6, 2747-56. DOI |
10 | Ockert D, Schirrmacher V, Beck N, et al (1996). Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res, 2, 21-28. |
11 | Patyar S, Joshi R, Byrav DSP, et al (2010). Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci, 17, 21-29. DOI ScienceOn |
12 | Peeters BP, Leeuw OS, Koch G, et al (1999). Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol, 73, 5001-9. |
13 | Pierrefite-Carle V, Baque P, Gavelli A, et al (1999). Cytosine deaminase/5-fluorocytosine-based vaccination against liver tumors: evidence of distant bystander effect. J Natl Cancer Inst, 91, 2014-19. DOI |
14 | Ravindra PV, Tiwari AK, Romer-Oberdorfer A, et al (1999). Generation of recombinant lentogenic Newcastle disease virus from cDNA. J Gen Virol, 80, 2987-95. DOI |
15 | Schirrmacher V, Haas C, Bonifer R, et al (1999). Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther, 6, 63-73. DOI ScienceOn |
16 | Schlag P, Manasterski M, Gerneth T, et al (1992). Active specific immunotherapy with Newcastle-disease-virusmodified autologous tumor cells following resection of liver metastases in colorectal cancer. Cancer Immunol Immunothe, 35, 325-30. DOI |
17 | Steiner HH, Bonsanto MM, Beckhove P, et al (2004). Anti-tumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol, 22, 4272-81. DOI ScienceOn |
18 | Schneider T, Gerhards R, Kirches E, Firsching R (2001). Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J Neurooncol, 53, 39-46. DOI ScienceOn |
19 | Springer CJ (2004). Suicide Gene Therapy, Methods and Reviews, (Totowa) New Jersey. |
20 | Springer CJ, Niculescu-Duvaz I (1996). Gene-directed enzyme prodrug therapy (GDEPT): choice of prodrugs. Adv Drug Deliv Rev, 22, 351-64. DOI ScienceOn |
21 | Stolworty TS, Aaron MK, Candice LW, et al (2008). Yeast cytosine deaminase mutants with increased thermostability impart sensitivity to 5-fluorocytosine. J Mol Biol, 377, 854-69. DOI ScienceOn |
22 | Topf N, Worgall S, Hackett NR, Crystal RG (1998). Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Gene Ther, 5, 507-13. DOI ScienceOn |
23 | Toshiaki T, Duflot-Dance A, Tiraby M, et al (2009). Bystander effect from cytosine deaminase and uracil phosphoribosyl transferase genes in vitro: a partial contribution of gap junctions. Cancer Lett, 282, 43-47. DOI ScienceOn |
24 | Vigil A, Martinez O, Chua MA, Garcia-Sastre A (2008). Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol Ther, 16, 1883-90. DOI |
25 | Zhao H, Peeters BP (2003). H. Recombinant Newcastle disease virus as a viral vector: effect of genomic location of foreign gene on gene expression and virus replication. J Gen Virol, 84, 781-88. DOI ScienceOn |
26 | Wallack MK, Sivanandham M, Balch CM, et al (1998). Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg, 187, 69-77. DOI ScienceOn |
27 | Zamarin D, Martinez-Sobrido L, Kelly K, et al (2009). Enhancement of oncolytic properties of recombinant Newcastle Disease Virus through antagonism of cellular innate immune responses. Mol Ther, 17, 697-706. DOI ScienceOn |
28 | Zamarin D, Vigil A, Kelly K, et al (2009). Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther, 16, 796-804. DOI ScienceOn |
29 | Batliwalla, Bateman, Serrano, et al (1998 ). A 15-year followup of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med, 4, 783-94. |
30 | Arica B, Calis S, Kas H, S, et al (2002). 5-Fluorouracil encapsulated alginate beads for the treatment of breast cancer. Int J Pharm, 242, 267-69. DOI ScienceOn |
31 | Bentires-Alj M, Hellin AC, Lechanteur C, et al (2000). Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis. Cancer Gene Ther, 7, 20-26. DOI ScienceOn |
32 | Bentires-Alj M, Hellin AC, Lechanteur C, et al (2000). Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis. Cancer Gene Ther, 7, 20-26. DOI ScienceOn |
33 | Cassel WA, Murray DR (1988). Treatment of stage II malignant melanoma patients with a Newcastle disease virus oncolysate. Nat Immun Cell Growth Regul, 7, 351-52. |
34 | Dachs GU, Hunt MA, Syddall S, et al (2009). Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules, 14, 4517-45. DOI ScienceOn |
35 | Fabian Z, Csatary CM, Szeberenyi J, et al (2007). p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines. J Virol, 81, 2817-30. DOI ScienceOn |
36 | Frederick MA (2002) (ed). Current Protocols in Molecular Biology, New York, John Wiley & Sons. |
37 | Fuchita M, Ardiani A, Zhao L, et al (2009). Bacterial cytosine deaminase mutants created by molecular engineering show improved 5-fluorocytosine-mediated cell killing in vitro and in vivo. Cancer Res, 69, 4791-99. DOI ScienceOn |